(PR-inside.com) http://www.biotherapharma.com - Biothera announced today it began dosing patients in the second arm of its metastatic colorectal cancer (mCRC) trial in August. This arm of the trial is evaluating the combination therapy of its lead drug candidate, Imprime PGG(R), with Erbitux(R), an anti-cancer monoclonal antibody from ImClone Systems. Unlike the first trial arm, the second treatment arm does not include chemotherapy. In the first arm of the trial, which was fully enrolled this past July, Imprime PGG was combined with Erbitux (cetuximab) and irinotecan, a chemotherapy drug, which is the standard of care for second- and third-line mCRC patients. ..
More...
More...